Investment Rating - The report maintains an "Outperform the Market" rating for the industry [2][48]. Core Insights - The silver economy in China is rapidly expanding, with the market size projected to grow from 4.3 trillion yuan in 2019 to 7.1 trillion yuan in 2023, and further to 8.3 trillion yuan in 2024. By 2030, the market is expected to exceed 16.2 trillion yuan, indicating significant growth potential [3][5][42]. - The new generation of elderly consumers, primarily those born in the 1960s and 1970s, exhibit different consumption habits compared to previous generations, focusing more on enjoyment and quality rather than just practicality [19][34]. Summary by Sections Market Size and Growth - The silver economy market size in China reached 4.3 trillion yuan in 2019, growing to 7.1 trillion yuan in 2023, and is expected to reach 8.3 trillion yuan in 2024. By 2030, it is projected to surpass 16.2 trillion yuan, with a compound annual growth rate (CAGR) of approximately 11.5% from 2025 to 2030 [3][5][42]. Consumer Behavior - The new elderly demographic is characterized by higher education levels and disposable income, leading to a shift in consumption from "saving" to "enjoyment." They prioritize health, quality, and emotional experiences in their purchasing decisions [19][25][34]. - Online shopping is becoming increasingly popular among the elderly, with 1.56 billion users aged 60 and above, representing 14.1% of total internet users. This demographic is significantly influenced by peer recommendations and social media [20][24]. Industry Trends - Retailers are adapting to the needs of elderly consumers by creating shopping environments that combine social interaction with purchasing. Companies like Bailian and Chongqing Department Store are developing tailored business models to cater to the preferences of this demographic [3][26][42]. - In the jewelry sector, older consumers remain a key market, with a focus on investment and brand loyalty. Companies like Caibai and Laofengxiang are enhancing their offerings to meet the demands of this consumer group [4][43]. Beauty and Healthcare - The beauty and healthcare market for the elderly is expanding, with a notable increase in the consumption of skincare and medical beauty services. The market for beauty products among consumers aged 50 and above is growing, with significant sales increases reported [34][37]. - The medical beauty sector is also expected to grow, with older consumers increasingly seeking anti-aging treatments and comprehensive care solutions [39][40]. Policy Support - Recent government policies are aimed at promoting the silver economy, emphasizing the importance of addressing the needs of the elderly population and fostering the development of related industries [9][12].

2月2日，A股市场整体下跌。截至收盘，上证指数收报4015.75点，下跌2.48%，深证成指收报 13824.35点，下跌2.69%，创业板指收报3264.11点，下跌2.46%，北证50指数下跌2.03%。 1. A股市场全天资金净流出539.77亿元 今日A股市场主力资金开盘净流出143.2亿元，尾盘净流出157.11亿元，A股市场全天资金净流出 539.77亿元。 | | | 沪深两市近五日主力资金流向情况(亿元) | | | | --- | --- | --- | --- | --- | | 日期 | | 净流入金额 开盘净流入 | | 尾盘净流入 超大单净买入 | | 2026-2-2 | -539.77 | -143. 20 | -157. 11 | -384. 36 | | 2026-1-30 | -595. 71 | -279.84 | -50. 70 | -303.01 | | 2026-1-29 | -602. 22 | -221.16 | -98.94 | -296. 09 | | 2026-1-28 | -274.87 | -58.90 | -29.34 | -118. 55 | | ...

Core Viewpoint - The Biotech Economy Index (970038) experienced a decline of 2.99%, closing at 2139.16 points on February 2, with a total trading volume of 26.538 billion yuan and a turnover rate of 2.97% [1] Group 1: Index Performance - On the day, only 2 out of the index's constituent stocks rose, with Aimeike leading the gain at 1.01%, while 48 stocks fell, with Dabeinong leading the decline at 10.02% [1] Group 2: Capital Flow - The net outflow of main funds from the Biotech Economy Index constituents totaled 1.249 billion yuan, while the net inflow from speculative funds was 262 million yuan, and the net inflow from retail investors was 988 million yuan [2]

Core Viewpoint - The arbitration case regarding the exclusive agency rights for AestheFill products has seen new developments, with REGEN Biotech, Inc. receiving a decision from the Shenzhen International Arbitration Court that revokes previous temporary measures against them, although the case is still under review [2][8]. Group 1: Arbitration Developments - On January 30, 2026, REGEN received a decision from the Shenzhen International Arbitration Court that revoked the temporary measures imposed on September 10, 2025, which restricted REGEN from selling AestheFill products in China and recognized DaTou Company as the exclusive distributor [2][8]. - The temporary measures had been in place since a request from DaTou Company, which claimed exclusive rights to AestheFill products in China [7][8]. - The arbitration case is ongoing, and the recent decision does not represent a final ruling on the matter [8]. Group 2: Company Actions and Responses - DaTou Company was granted exclusive distribution rights for AestheFill products in mainland China through an agreement signed in August 2022 [3]. - In July 2025, REGEN sent a termination notice to DaTou, claiming violations of the agreement and citing reputational damage due to actions by DaTou's parent company, Jiangsu Wuzhong [4][5]. - Jiangsu Wuzhong has publicly defended DaTou's rights, asserting that the exclusive agency agreement remains valid until August 28, 2032 [4]. Group 3: Financial Performance - Jiangsu Wuzhong's stock was delisted on December 31, 2025, due to significant financial irregularities, including inflated revenues and undisclosed related-party transactions [9]. - AestheFill sales accounted for 20.42% of Jiangsu Wuzhong's revenue in 2024, with a significant contribution to its gross profit [10]. - For the first three quarters of 2025, Jiangsu Wuzhong reported a 38.85% decline in revenue, leading to a net loss [10]. Group 4: Market Context - Aimeike, the parent company of REGEN, has experienced declining revenue and net profit, with a 21.49% drop in revenue for the first three quarters of 2025 [11]. - The overall medical aesthetics market in China is facing slower growth, attributed to increased competition and a challenging macroeconomic environment [11].

Core Viewpoint - The medical beauty sector experienced a rise of 2.68% on February 2, with Huaxi Biological leading the gains, while the overall market indices, Shanghai Composite and Shenzhen Component, saw declines of 2.48% and 2.69% respectively [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4015.75, down 2.48% [1] - The Shenzhen Component Index closed at 13824.35, down 2.69% [1] - The medical beauty sector stocks showed varied performance, with Huaxi Biological rising by 5.24% to a closing price of 47.18 [1] Group 2: Stock Details - Huaxi Biological (688363) had a trading volume of 118,200 shares and a transaction value of 562 million yuan [1] - Aimei Ke (300896) closed at 141.14, up 1.01%, with a trading volume of 47,500 shares and a transaction value of 683 million yuan [1] - ST Meigu (000615) closed at 3.08, up 0.33%, with a trading volume of 115,100 shares [1] - Jinbo Biological (920982) closed at 214.89, down 2.94%, with a trading volume of 9,949 shares and a transaction value of 217 million yuan [1] Group 3: Fund Flow Analysis - The medical beauty sector saw a net inflow of 100 million yuan from main funds, while retail investors experienced a net outflow of 59.89 million yuan [1] - Aimei Ke had a main fund net inflow of 55.54 million yuan, but a net outflow of 33.36 million yuan from retail investors [2] - Huaxi Biological experienced a main fund net inflow of 44.73 million yuan, with retail investors showing a net outflow of 27.92 million yuan [2]

Group 1: ETF Performance - As of February 2, 2026, the Medical Equipment ETF (159873) had a turnover of 5.82% with a transaction volume of 14.6087 million yuan, while the tracked index, the CSI All Share Healthcare Equipment and Services Index (H30178), fell by 1.44% [1] - The Medical Equipment ETF (159873) saw a net subscription of 11 million shares during the trading session [2] - The Biopharmaceutical ETF (159859) had a turnover of 3.87% with a transaction volume of 142 million yuan, and the corresponding index, the National Biopharmaceutical Index (399441), decreased by 2.18% [2] Group 2: Fund Flows - The Medical Equipment ETF (159873) experienced a net inflow of 4.2585 million yuan, with a total of 22.8076 million yuan net inflow over the last five trading days [2] - The Biopharmaceutical ETF (159859) achieved a new high in scale at 3.705 billion yuan and a new high in shares at 9.396 billion shares as of January 30 [3] - The Biopharmaceutical ETF (159859) has seen continuous net inflows over the past ten days, totaling 425 million yuan [3] Group 3: Sector Insights - The Medical Equipment ETF (159873) has a high content of brain-computer interface technology, accounting for over 17%, indicating strong technological attributes [3] - The overall industry landscape for medical devices is improving, with leading companies showing performance recovery in Q3, suggesting potential for future capital inflows [6] - The innovative drug sector is expected to see a recovery phase, with a focus on domestic innovation and increased global participation, indicating a positive outlook for investment opportunities [7]

消息面上，2月1日，华为云正式宣布，"行业AI梦工厂"首个落地成果——智慧医疗专区亮相，同时，即 日起启动公开测试，率先开放健康管理与病理AI辅助诊断两大核心功能，面向广大医疗机构、医生及 大众开放服务与体验。该专区深度融合上海瑞金医院等顶尖医疗机构的临床经验与华为在云、AI及ICT 领域的技术积累，旨在构建一个端到端的AI赋能平台。 光大证券强调，在医保控费（DRG/DIP）与大模型技术奇点双重驱动下，AI已成为医疗新基建的核心 生产力；其中AI制药因能显著缩短研发周期、药企付费意愿最强，AI医学影像是当前落地最成熟的赛 道，而AI慢病管理和AI手术机器人则分别依托商业保险降本逻辑与医疗资源均衡逻辑，具备强国产化 替代潜力。未来竞争核心在于独家高质量私有数据与业务场景闭环能力。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本， 以反映兼具盈利性与成长性的医药及医疗器械上市公司证券的整体表现。 截至2026年2月2日 10:44，中证医药及医疗器械创新指数(931484)下 ...

Core Insights - The A-share market experienced fluctuations with the Shanghai Composite Index falling by 0.96% to 4117.95 points, while the Shenzhen Component Index decreased by 0.66%. The ChiNext Index, however, rose by 1.27% [1][7] - The total trading volume in the A-share market was 2.86 trillion RMB, with nearly 2900 stocks declining. The communication sector led the gains, while the non-ferrous metals sector saw the largest losses [1][7] - In the Hong Kong market, the Hang Seng Index dropped by 2.08%, and the Hang Seng Tech Index fell by 2.1%. In the overseas markets, all three major U.S. stock indices declined, with the Dow Jones down by 0.36%, the S&P 500 down by 0.43%, and the Nasdaq down by 0.94% [1][7] Important News - The Central Committee of the Communist Party of China emphasized the acceleration of the new round of technological revolution and industrial transformation, highlighting the importance of leveraging comparative advantages to promote breakthroughs in future industries [2][8] - The National Bureau of Statistics reported that the manufacturing PMI for January was 49.3%, a decrease of 0.8 percentage points month-on-month. The non-manufacturing PMI also fell to 49.4%, indicating a decline in business activity due to seasonal factors and insufficient market demand [2][8] Sector Analysis - In the social services sector, the proportion of heavy positions in funds increased, with 286 funds holding shares, up by 109 from the previous quarter. The total market value of holdings reached 5.57 billion RMB, an increase of 0.975 billion RMB [9][10] - The heavy position ratio for the social services sector was 0.06%, up by 0.01 percentage points, ranking 27th among 31 sectors, indicating potential for rebound as it remains below the 5-year average of 0.34% [9][10] - The hospitality and restaurant sectors showed slight recovery, while the education sector saw a significant decline in heavy position ratios [9][10] Individual Stocks - Leading stocks in the social services sector saw increased holdings, with the top ten stocks' combined heavy position ratio rising to 0.058%, an increase of 0.013 percentage points from the previous quarter. Notable stocks include Huace Testing, Shoulv Hotel, and JiuHua Tourism [10][11] - The report suggests focusing on companies benefiting from the upcoming long holiday and those positioned to take advantage of the Hainan Free Trade Port's opportunities [11] Beauty and Personal Care Sector - The beauty and personal care sector saw a decrease in fund allocation, with the total market value of A-shares at 255.096 billion RMB, down by 10.43% from the previous quarter. The fund allocation ratio was 0.14%, a decrease of 0.06 percentage points [12][13] - The personal care and cosmetics segments remain in a low allocation zone, while the medical beauty segment is in an over-allocated position [12][13] - Key stocks in the beauty and personal care sector include Jinbo Biological, Aimeike, and Baiya Shares, with their heavy position ratios declining compared to the previous quarter [14]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights the emergence of HBN, a leading domestic skincare brand, which has submitted its prospectus to the Hong Kong Stock Exchange, indicating strong growth potential in the efficacy skincare market [3][24] - The report emphasizes the importance of emotional consumption themes and recommends high-quality companies in high-growth sectors, including gold and jewelry, offline retail, cosmetics, and medical aesthetics [6][49] Summary by Sections Retail and Social Services Market Review - For the week of January 26 to January 30, the retail and social services indices closed at 2435.34 points and 9283.84 points, respectively, with declines of 4.18% and 3.45% [5][14] - The jewelry sector showed the highest growth, with a weekly increase of 7.07% and a year-to-date increase of 19.39% [15][18] Industry Dynamics: HBN and Efficacy Skincare - HBN, established in 2019, is the largest domestic skincare brand in the efficacy segment, focusing on visible results and innovative product strategies [24][25] - The brand's core products, including the "A Retinol" series, have achieved significant sales milestones, with a strong emphasis on scientific validation and consumer trust [29][33] Investment Recommendations - Investment focus areas include: - Gold and jewelry brands with differentiated product offerings, recommending companies like Laopuhuang and Chaohongji [6][49] - Offline retail companies adapting to market changes, with recommendations for Yonghui Supermarket and Aiyingshi [6][49] - Domestic cosmetics brands that emphasize emotional value and safety, recommending brands like Maogeping and Proya [6][50] - Medical aesthetics firms with unique product lines, recommending Meilitiantian Medical Health and Aimeike [6][51]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights the emergence of HBN, a leading domestic skincare brand, which has submitted its prospectus to the Hong Kong Stock Exchange, indicating strong growth potential in the efficacy skincare market [3][24] - The report emphasizes the importance of emotional consumption themes and suggests focusing on high-quality companies in high-growth sectors [6][49] Summary by Sections Industry Performance Overview - The commercial retail and social services indices reported declines of 4.18% and 3.45% respectively during the week of January 26 to January 30, 2026, ranking 26th and 23rd among 31 primary industries [5][14] - The jewelry sector showed the highest growth, with a weekly increase of 7.07% and a year-to-date increase of 19.39% [15][18] Key Industry Developments - HBN, established in 2019, is recognized as the largest domestic skincare brand in the efficacy skincare segment, with a market share of 0.8% in the Chinese improvement skincare market as of 2024 [24][25] - HBN's revenue for the first three quarters of 2025 reached 1.51 billion yuan, a year-on-year increase of 10.2%, with high-efficacy skincare products accounting for 78.6% of total revenue [29] Investment Recommendations - Investment Theme 1: Focus on high-end gold and fashion jewelry brands, recommending companies like Laopuhuangjin and Chaohongji [6][49] - Investment Theme 2: Highlighting retail companies that adapt to emotional value and intelligent trends, with recommendations for Yonghui Supermarket and Aiyingshi [6][49] - Investment Theme 3: Emphasizing beauty and personal care brands that innovate with emotional value and safe ingredients, recommending brands like Maogeping and Pola [6][50] - Investment Theme 4: Targeting differentiated medical beauty product manufacturers and leading medical beauty institutions, recommending companies like Aimeike and Meilitiantian [6][51]